Search clinical trials for: Interleukin-2

Total 48395 results

Samsung Medical Center

Recruiting

Response-based Treatment of High-risk Neuroblastoma

Newly Diagnosed High Risk Neuroblastoma

Korea, Republic of
Camillo Ricordi and Jay Skyler
Diabetes Research Institute Foundation

Not yet recruiting

Diabetes Islet Preservation Immune Treatment (DIPIT)

Autoimmune Diseases | Diabetes Mellitus | Hypoglycemia | Diabetes Mellitus, Type 1

United States
St. Anna Kinderkrebsforschung

Recruiting

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

Neuroblastoma

Norway, Czechia, United Kingdom, France, Spain, Belgium, Switzerland, Hungary, Israel, Australia, Italy, Austria, Denmark, Greece, Ireland, Poland, Portugal, Slovakia, Slovenia, Sweden
National Cancer Institute (NCI)

Active, not recruiting

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Recurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 Neuroblastoma

United States, Canada, Australia, New Zealand, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

Recurrent Ovarian Carcinoma | HLA-A*0201 Positive Cells Present | COL6A3 Positive | PRAME Positive

United States
Philogen S.p.A.
Merck Sharp & Dohme LLC

Active, not recruiting

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients (INTACT/MeRCI)

Melanoma Stage IV | Melanoma Stage III

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Dana-Farber Cancer Institute
Prometheus Laboratories

Active, not recruiting

A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD

Chronic Graft-versus-host-disease

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI); Prometheus Laboratories

Active, not recruiting

Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

Chronic Graft-versus-host Disease

United States
St. Jude Children's Research Hospital
Cookies for Kids' Cancer; CURE Childhood Cancer, Inc.

Active, not recruiting

Therapy for Children With Advanced Stage Neuroblastoma

Neuroblastoma

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Iovance Biotherapeutics

Active, not recruiting

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Malignant Solid Neoplasm | Metastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Platinum-Resistant Ovarian Carcinoma | Metastatic Pancreatic Ductal Adenocarcinoma | Metastatic Ovarian Carcinoma and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

Metastatic Melanoma

United States
Gilead Sciences

Terminated

Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers

Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer

United States
Jonsson Comprehensive Cancer Center
California Institute for Regenerative Medicine (CIRM)

Terminated

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT)

Sarcoma | Unresectable Malignant Neoplasm | Locally Advanced Malignant Neoplasm | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive

United States
Philogen S.p.A.

Terminated

A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma (DLBCL)

Germany
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Novartis; Lymphoma Research Foundation

Completed

Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma

Lymphoma

United States
CINJRegulatory
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Terminated

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)

Completed

FT516 and IL2 With Enoblituzumab for Ovarian Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer | Fallopian Tube Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
University Health Network, Toronto

Completed

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

Pleural Mesothelioma

Canada
University of Cologne

Terminated

NB2013-HR German (GPOH) / Dutch (DCOG) Trial (NB2013-HR)

Neuroblastoma

Germany
St. Jude Children's Research Hospital
Assisi Foundation; Cookies for Kids' Cancer

Completed

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood B-Lymphoblastic Lymphoma

United States
PACT Pharma, Inc.

Suspended

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

Solid Tumor

United States
The First Hospital of Jilin University

Completed

The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura (HSP)

Purpura, Schoenlein-Henoch

China
Philogen S.p.A.

Active, not recruiting

A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

Metastatic Melanoma Stage IV

Italy, Germany
Washington University School of Medicine
Wugen, Inc.

Withdrawn

Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS

Myelodysplastic Syndromes | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid Leukemia
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); University of Southern California; University... and other collaborators

Completed

Study of Gene Modified Immune Cells in Patients With Advanced Melanoma (F5)

Metastatic Melanoma

United States
National Institute of Allergy and Infectious Diseases...

Completed

Umbrella Study for HIV Infected Adults Enrolled in NIAID-Funded Interleukin-2 Studies

HIV Infections

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

Recurrent Non-Small Cell Lung Carcinoma | Recurrent Pleural Malignant Mesothelioma | Stage III Pleural Malignant Mesothelioma AJCC v7 | Stage IV Pleural Malignant Mesothelioma AJCC v7 | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | HLA-A*0201 Positive... and other conditions

United States
University of California, San Diego

Completed

Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.

Schizophrenia

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma

High Risk Neuroblastoma

United States
Centre Hospitalier Universitaire Vaudois

Terminated

Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors

Solid Tumor, Adult

Switzerland
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Withdrawn

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM)

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive Tumor Cells Present

United States
Roswell Park Cancer Institute
Iovance Biotherapeutics, Inc.

Withdrawn

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial Carcinoma

United States
University of Wisconsin, Madison
National Cancer Institute (NCI); EMD Serono

Completed

Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma

Melanoma

United States
University Health Network, Toronto

Completed

Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma

Metastatic, Stage III or Stage IV, Melanoma

Canada
Beijing YouAn Hospital

Unknown

Study of Adoptive Transfer of iNKT Cells Combined With TACE to Treat Advanced HCC

Hepatocellular Carcinoma

China
University Hospital, Bordeaux

Completed

Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment (ANEMIL)

Autoimmune Hemolytic Anemia

France
Massachusetts General Hospital

Completed

Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits

Attention Deficit Hyperactivity Disorder (ADHD) | Deficient Emotional Self-Regulation (DESR)

United States
National Cancer Institute (NCI)

Terminated

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

Metastatic Uveal Melanoma | Metastatic Ocular Melanoma

United States
First Affiliated Hospital of Guangxi Medical University

Unknown

Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of Chimerism

Beta Thalassemia Major

China
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD (IL2 for GVHD)

Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | AML | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myeloproliferative Disorder | ALL | Non-malignant Diseases Requiring Allogeneic HSCT

United States
Stanley H. Appel, MD

Unknown

T-Regulatory Cells in Amyotrophic Lateral Sclerosis

ALS (Amyotrophic Lateral Sclerosis)

United States
Beijing YouAn Hospital

Unknown

Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC

Hepatocellular Carcinoma

China
Masonic Cancer Center, University of Minnesota

Completed

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

Stage IV Melanoma

United States
Masonic Cancer Center, University of Minnesota

Terminated

T-Cell Depleted Double UCB for Refractory AML

Acute Myelogenous Leukemia | Refractory Acute Myelogenous Leukemia

United States
Masonic Cancer Center, University of Minnesota

Terminated

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Masonic Cancer Center, University of Minnesota

Terminated

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

Myelodysplastic Syndromes | Leukemia

United States
St. Jude Children's Research Hospital

Completed

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

Lymphoma | Neuroblastoma | High-risk Tumor

United States

Search clinical trials for: Interleukin-2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations